**Optmatch** is a unified suite of tools for matching in veracity of these approximations. The function observational studies. **Ritools** provides the basic tools xBalance() implements randomization based for diagnostic checks and effect estimation in matching hypothesis tests based on the normal approximations and randomization based analysis. for sum statistics.

# Case Study: The Effect of Deadlines on Drug Safety

The Prescription Drug User Fee Act (PDUFA) of 1992 required the US Food and Drug Administration to act on 90% of "standard" drugs within 12 months. This was the first time that time pressure became a part of the assessment of drug safety in the USA. Our question is: **Does Haste make Waste?** Olson (2002,2004) says yes. Grabowski and Wang (2006) say no.

Seven drugs submitted and approved under the new regime were withdrawn for safety reasons (ex: the Cholesterol treatment Baycol caused potentially fatal muscle disorders; the Parkinson's treatment, Tasmar, caused liver failure, others withdrawn include Duract, Famvir, Posicor, Prelay, and Rezulin).

# Analytic Strategy

### Strengthen Our Argument for Ignorability using **Choice and Adjustment:**

**Choose** drugs submitted in a small window of time around the discontinuity that occurred on Sep 1, 1992 (± 4 years): 98 drugs pre-PDUFA, 121 drugs post-PDUFA.

Gently **adjust** using full matching (Hansen 2004) and  $bal1 < -xBalance(z \sim x_1 + ... + x_k, \sim priority, data=fdapdufa, chisquare.test=TRUE)$ a wide caliper on a propensity score (3 sd), which print(bal1) excludes 2 out of the 98 controls. st.sig

Test for balance using only assumptions about Z|X; Re-match if necessary.

### **Estimate Effects using Randomization Inference:**

Specify a variety of hypotheses about the attributable effect (Rosenbaum, 2001).

Test these hypotheses.

The set of hypotheses accepted at some  $\alpha$  is a 100(1α) Cl.

## A Randomization Based Test for Balance using RItools.

Well known randomization tests like those proposed by Fisher or Mantel and Haenszel represent null hypotheses with test statistics that are all members of the class of sum statistics t(Z,r);

 $t(\mathbf{Z},\mathbf{r}) = \mathbf{Z}^{\mathsf{T}}\mathbf{q}$ 

where **Z** records treatment assignment, **r** represents response or outcome, and **q** is some function of **r** (see Rosenbaum 2002, Chapter 2).

Sum statistics have well known normal approximations, allowing us to test hypotheses and produce confidence Pre: X-squared = 83.018, df = 55, p-value = 0.00867 Post: X-squared = 83.486, df = 55, p-value = 0.00791 intervals quickly. Since the exact tests are available The hypothesis of balance is rejected, with or without either via analytic development (e.g. mantelhaen.test) stratification on "priority." or simulation or sampling, we can always check the

# **Ritools and Optmatch: Tools for the Analysis of Observational Studies (à la Rosenbaum 2002)** Jake Bowers<sup>1</sup> and Ben Hansen<sup>2</sup>

xBalance

package:RItools

R Documentation

STANDARDIZED DIFFERENCES FOR STRATIFIED COMPARISONS

Description:

Given covariates, a treatment variable, and a stratifying factor calculates standardized differences (biases) along each covariat with and without the stratification. Also, tests for conditiona independence of the treatment variable and the covariates within strata.

<u>Usage</u>:

xBalance(fmla, groups, data, chisquare.test=FALSE)

<u>Arguments:</u>

- fmla: A formula containing an indicator of treatment assignment o the left hand side and covariates at right.
- groups: A formula with no left hand side and a single term, a stratifying factor, on the right hand side.
- data: A data frame in which the preceding formulas are to be evaluated.
- chisquare.test: Logical flag as to whether to perform optional chisquare tests for global departure from randomization distribution

### Initial Balance

#### We stratify on two kinds of drugs: "priority" (post-1992 deadline of 6 months) and "standard" (post-1992) deadline of 12 months).

	•	pre.sig	<pre>post.difference</pre>	post
media	0.08745		0.09759	
I(prevgenxA/1000)	0.16445		0.15179	
prevgenxANA	0.05222		0.03739	
dthrtgenA	-0.21066		-0.19159	
dthrtgenANA	0.27672	*	0.25807	
I(hhospdisc/1e+05)	-0.09987		-0.10916	
orderent	-0.02537		-0.06041	
fsubmitsA	0.02939		0.05432	
fsubmitsANA	-0.30854	*	-0.33747	
I(medline1total/1000)	-0.17449		-0.16235	
I(medline3total/1000)	-0.26091	•	-0.24556	
I(medline1safetytotal/10000)	-0.27009	*	-0.24983	
I(medline3safetytotal/1000)	-0.22926	•	-0.20845	
factor(discodeA)1600	0.21353		0.20423	
factor(discodeA)2300	-0.09396		-0.10720	
factor(discodeA)2500	-0.02884		-0.03216	
factor(discodeA)3100	0.07719		0.07689	
factor(discodeA)3230	-0.10414		-0.11445	
factor(discodeA)3300	-0.02030		-0.00510	
factor(discodeA)3500	-0.34503	*	-0.32153	
factor(discodeA)3700	-0.16670		-0.15383	
factor(discodeA)3800	0.17361		0.17778	
factor(discodeA)4050	0.17361		0.16605	
factor(discodeA)4100	-0.21478		-0.21190	
factor(discodeA)4140	-0.02030		-0.01679	
factor(discodeA)4400	-0.14851		-0.15640	
factor(discodeA)5200	-0.02030		-0.01679	
factor(discodeA)5260	-0.21478		-0.22366	
factor(discodeA)5400	-0.02884		-0.03216	
factor(discodeA)5500	0.04173		0.02151	
factor(discodeA)5610	0.10861		0.10575	
factor(discodeA)6100	-0.02030		-0.01679	
factor(discodeA)6140	0.09525		0.12291	
factor(discodeA)6200	0.17361		0.17778	
factor(discodeA)6400	-0.33995	*	-0.34575	
factor(discodeA)6500	-0.21478		-0.22366	
factor(discodeA)6640	-0.02030		-0.02848	
factor(discodeA)7500	-0.21478		-0.21190	
factor(discodeA)10100	-0.02030		-0.01679	
factor(discodeA)10400	-0.02884		-0.03216	
factor(discodeA)10800	-0.21478		-0.20015	
factor(discodeA)10820	-0.21478		-0.22366	
factor(discodeA)10900	0.05418		0.04440	
factor(discodeA)11600	-0.10414		-0.10488	
factor(discodeA)11700	-0.21478		-0.22366	
factor(discodeA)12300	0.17361		0.17778	
factor(discodeA)13000	-0.21478		-0.21190	
factor(discodeA)13100	0.17361		0.16605	
factor(discodeA)13120	-0.02030		-0.02848	
factor(discodeA)80200	0.21353		0.21385	
factor(discodeA)80300	-0.02030		-0.00510	
factor(discodeA)80700	0.21353		0.20423	
factor(discodeA)82200	0.27803	*	0.28846	
factor(discodeA)85300	-0.03549		-0.04298	
factor(discodeA)88888	-0.05938		-0.07903	
Pre: $X$ -squared = 83.018, df	= 55. p-value =	= 0.00867	7	

# Full Matching Using Optmatch

First, make a list of distance matrices (one matrix for priority and one for standard drugs), including a caliper.


absDist <- function(trtvar,data,scalarname,cal=Inf){</pre> sclr <- data[names(trtvar), scalarname]</pre> names(sclr) <- names(trtvar)</pre> dist<-abs(outer(sclr[trtvar],sclr[!trtvar], '-'))</pre> dist/(dist<=cal)}</pre>

psdistlist<-makedist(pdufaT~priorityF,data=fdapdufa,</pre> fn=absDist,scalarname="ps4yr",cal=3)

#### thefm<-fullmatch(psdistlist)</pre>

		Match	ed Sets			
	Standard D	rugs		Priority Drugs		
Set	PrePDUFA	PostPDUFA	Set	PrePDUFA	PostPDUFA	
St.01	1	0	Pr.1	1	13	
St.02	1	0	Pr.10	2	1	
St.1	1	21	Pr.13	1	5	
St.10	1	1	Pr.2	5	1	
St.14	1	4	Pr.21	1	3	
St.2	1	15	Pr.3	1	2	
St.21	1	1	Pr.30	2	1	
St.24	1	1	Pr.31	6	1	
St.27	1	1	Pr.33	15	1	
St.28	1	2	Pr.4	1	9	
St.37	1	1	Pr.5	1	1	
St.39	1	1	Pr.6	1	1	
St.40	1	1				
St.46	36	1				
St.5	1	14				
St.53	1	1				
St.59	3	1				
St.6	1	4				
St.7	1	2				
St.71	1	1				
St.75	1	1				
St.77	1	1				
St.8	1	1				
St.9	1	6				

### **Discontinuity +Matching=Balance**



thefmbal<-xBalance(balpsformula,~thefm,data=fdapdufa,chisquare.test=TRUE)

regime:

ways:

#### # Attri

##the Matrix deltas (96x6) contains all of the allowable attributions tc <- table(pdufa=fdapdufa[good,"pdufaF"],</pre>

myattrib.arr<-array(0,dim=c(2,2,34,nrow(deltas)),</pre>

myattrib.arr[2,1,clevs,]<-myattrib.arr[2,1,clevs,]-t(deltas)</pre> myattrib.arr[2,2,clevs,]<-t(deltas)</pre>

thezs<-rdz(tc,myattrib.arr)</pre> aes1<-data.frame(A=theAs,Z=thezs,p=pnorm(abs(thezs),lower=FALSE)\*2)</pre> tapply(aes1\$p,aes1\$A,range)

How many safety based withdrawals can be attributed to the change in the FDA rules? Zero is probable, but 6 is more probable than 0.

# References

Bowers, Jake and Ben B. Hansen. 2005. "Attributing Effects to A Cluster Randomized Get-Out-The-Vote Campaign: An Application of Randomization Inference Using Full Matching." Unpublished manuscript.

1993-2003." Unpublished manuscript. Hansen, Ben B. 2006. "Appraising Covariate Balance after Assignment to Treatment by Groups." Technical Report 436 Statistics Department: University of Michigan

Hansen, Ben B. 2004. "Full Matching in an Observational Study of Coaching for the SAT." Journal of the American Statistical Association 99:609.

Hansen, Ben B. and Stephanie Olsen Klopfer. 2005. "Optimal full matching and related designs via network flows." Technical Report 416 Statistics Department, University of Michigan. Olson, Mary K. 2002. "Pharmaceutical Policy Change and the Safety of New Drugs." Journal of Law and

Olson, Mary K. 2004. "Are novel drugs more risky for patients than less novel drugs?" Journal of Health *Economics* 23:1135–1158.

Rosenbaum, Paul R. 1989. "Optimal Matching for Observational Studies." Journal of the American Statistical Association 84:1024–1032.

Rosenbaum, Paul R. 2001. "Effects Attributable to Treatment: Inference in experiments and observational studies with a discrete pivot." Biometrika 88:219–231. Rosenbaum, Paul R. 2002. Observational Studies. Springer

# Attributing Effects to the Change in **Regulatory Regime.**

We define a treatment effect at the unit level:

 $\tau_i = r_{ti} - r_{ci}$ 

The estimand is the effect attributable to the PDUFA

	S n <sub>s</sub>
$t(\mathbf{Z},\mathbf{r}) =$	$\sum \sum Z_{si}r_{si}$
	s=1 <i>i</i> =1

We can test for A=0...7 by adjusting the outcomes in 96

A =	0	1	2	3	4	5	6	7
ributions Possible=	1	6	16	25	25	16	6	1

withdraw=fdapdufa[good,"anywithdraw"]

match=thefm[good,drop=TRUE],exclude=NULL)

dimnames=list(0:1,0:1, dimnames(tc)[[3]],1:nrow(deltas))) myattrib.arr[1,1,,]<-tc["PostDiscont",'0',]</pre> myattrib.arr[2,1,,]<-tc["PostDiscont",'1',]</pre>

Tests of  $t(\mathbf{Z},\mathbf{r})$  for each possible attribution using the same kind of normal approximation this time with the rdz() function, yielded a CI containing all of the possible attributions, including 0.

	0	1	2	3	4	5	6	7	
р р	0.3	0.3 0.5	0.3 0.7	0.3 0.9	0.3 1.0	0.5 0.9	0.7 0.9	.6	

Grabowski, Henry and Y. Richard Wang. 2006. "Determinants of New Drug Safety in the United States,

*Economics* XLV:615–642.